Ion Beam Applications SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Ion Beam Applications SA Signs Term Sheet For Disposal Of Cisbio Bioassays SAS
Ion Beam Applications SA announced that it has signed a term sheet for the sale of its Business Unit Cisbio Bioassays SAS. Following the Company's decision to refocus on its core businesses in radiation therapy (proton therapy, dosimetry) and accelerators for radiopharmaceuticals and industrial applications, the Company made the decision to dispose of its Bioassays division. The Company's Board held on May 8, 2013 has approved the signature of a term sheet with a European private equity firm. The projected value of the transaction is approximately EUR 25 million, a price close to the current book value of the Bioassays net assets in the Company's consolidated Financial Statement for 2012. As per the term sheet, the Bioassays business will be sold to a new company in which the Company would keep a minority stake of approximately 15%. Financing will be secured by the seller through a vendor note for an amount of EUR 7.5 million, the closing of the transaction is therefore not subject to bank financing.
Latest Key Developments in Advanced
- Hamilton Thorne announces private placement unit offering of up to C$750,000
- Accelera Innovations Inc announces purchase agreement of SCI Home Health Inc
- Varian Medical Systems Inc gives Q1, FY 2015 EPS guidance below analysts' estimates
- Nanosphere Inc prices $20 million public offering of common stock
- Share this
- Digg this